{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T17:35:28Z","timestamp":1783532128199,"version":"3.55.0"},"reference-count":23,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":834,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematol Oncol"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1002\/hon.2078","type":"journal-article","created":{"date-parts":[[2013,5,21]],"date-time":"2013-05-21T05:11:26Z","timestamp":1369113086000},"page":"10-15","source":"Crossref","is-referenced-by-count":25,"title":["Efficacy of<sup>90<\/sup>Yttrium-ibritumomab tiuxetan in relapsed\/refractory extranodal marginal-zone lymphoma"],"prefix":"10.1002","volume":"32","author":[{"given":"Anna","family":"Vanazzi","sequence":"first","affiliation":[{"name":"Hematoncology Division; European Institute of Oncology; Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Grana","sequence":"additional","affiliation":[{"name":"Nuclear Medicine; European Institute of Oncology; Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiano","family":"Crosta","sequence":"additional","affiliation":[{"name":"Endoscopy Division; European Institute of Oncology; Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Pruneri","sequence":"additional","affiliation":[{"name":"Pathology Department; European Institute of Oncology; Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Rizzo","sequence":"additional","affiliation":[{"name":"Radiology Department; European Institute of Oncology; Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Radice","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics; European Institute of Oncology; Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonello","family":"Pinto","sequence":"additional","affiliation":[{"name":"Hematology Division; Istituto Nazionale Tumori Fondazione Pascale; Naples Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana","family":"Calabrese","sequence":"additional","affiliation":[{"name":"Hematoncology Division; European Institute of Oncology; Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Paganelli","sequence":"additional","affiliation":[{"name":"Nuclear Medicine; European Institute of Oncology; Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Martinelli","sequence":"additional","affiliation":[{"name":"Hematoncology Division; European Institute of Oncology; Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,5,20]]},"reference":[{"key":"10.1002\/hon.2078-BIB0001|hon2078-cit-0001","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1182\/asheducation-2005.1.307","article-title":"Clinical presentation and management of marginal zone lymphomas","volume":"1","author":"Thieblemont","year":"2005","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"26","key":"10.1002\/hon.2078-BIB0002|hon2078-cit-0002","doi-asserted-by":"crossref","first-page":"6415","DOI":"10.1200\/JCO.2005.05.018","article-title":"State-of-the-Art therapeutics: marginal-zone lymphoma","volume":"23","author":"Bertoni","year":"2005","journal-title":"Clin Oncol"},{"issue":"5-6","key":"10.1002\/hon.2078-BIB0003|hon2078-cit-0003","doi-asserted-by":"crossref","first-page":"527","DOI":"10.3109\/10428199709050889","article-title":"Clinical features, treatment and outcome in a series of 93 patients with low-grade gastric MALT lymphoma","volume":"26","author":"Pinotti","year":"1997","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"10.1002\/hon.2078-BIB0004|hon2078-cit-0004","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1182\/blood.V95.12.4014","article-title":"Translocation t(11;18) absent in early gastric marginal zone B-cell lymphoma of MALT type responding to eradication of Helicobacter pylori infection","volume":"95","author":"Alpen","year":"2000","journal-title":"Blood"},{"issue":"2","key":"10.1002\/hon.2078-BIB0005|hon2078-cit-0005","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/1042819021000035680","article-title":"Outcome in relation to treatment modalities in 48 patients with localized gastric MALT lymphoma: a retrospective study of patients treated during 1976-2001","volume":"44","author":"Thieblemont","year":"2003","journal-title":"Leuk Lymphoma"},{"issue":"22","key":"10.1002\/hon.2078-BIB0006|hon2078-cit-0006","doi-asserted-by":"crossref","first-page":"4157","DOI":"10.1200\/JCO.2003.06.085","article-title":"Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome","volume":"21","author":"Tsang","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1002\/hon.2078-BIB0007|hon2078-cit-0007","first-page":"104","volume-title":"MALT Lymphomas","author":"Gospodarowicz","year":"2004"},{"issue":"2","key":"10.1002\/hon.2078-BIB0008|hon2078-cit-0008","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1182\/blood.V96.2.410","article-title":"The gastric marginal zone B-cell lymphoma of MALT type","volume":"96","author":"Zucca","year":"2000","journal-title":"Blood"},{"key":"10.1002\/hon.2078-BIB0009|hon2078-cit-0009","first-page":"99","volume-title":"MALT Lymphomas","author":"Conconi","year":"2004"},{"issue":"10","key":"10.1002\/hon.2078-BIB0010|hon2078-cit-0010","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1200\/JCO.1995.13.10.2524","article-title":"Efficacy of single-agent chemotherapy in low-grade B-cell mucosa-associated lymphoid tissue lymphoma with prominent gastric expression","volume":"13","author":"Hammel","year":"1995","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1002\/hon.2078-BIB0011|hon2078-cit-0011","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1002\/cncr.20237","article-title":"Fludarabine-containing chemotherapy as frontline treatment of non gastrointestinal mucosa-associated lymphoid tissue lymphoma","volume":"100","author":"Zinzani","year":"2004","journal-title":"Cancer"},{"issue":"18","key":"10.1002\/hon.2078-BIB0012|hon2078-cit-0012","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.1200\/JCO.2002.05.117","article-title":"Treatment of extranodal marginal zone b-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a phase II study","volume":"20","author":"Jager","year":"2002","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1002\/hon.2078-BIB0013|hon2078-cit-0013","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1093\/annonc\/mdg492","article-title":"Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) with mitoxantrone, chlorambucil and prednisone (MCP)","volume":"14","author":"Wohrer","year":"2003","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1002\/hon.2078-BIB0014|hon2078-cit-0014","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1182\/blood-2002-11-3496","article-title":"Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type","volume":"102","author":"Conconi","year":"2003","journal-title":"Blood"},{"issue":"9","key":"10.1002\/hon.2078-BIB0015|hon2078-cit-0015","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1200\/JCO.2005.08.128","article-title":"Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy","volume":"23","author":"Martinelli","year":"2005","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1002\/hon.2078-BIB0016|hon2078-cit-0016","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1200\/JCO.2011.40.6272","article-title":"Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 randomized study","volume":"31","author":"Zucca","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1002\/hon.2078-BIB0017|hon2078-cit-0017","first-page":"465","article-title":"Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: Combined data from 4 clinical trials","volume":"44","author":"Wiseman","year":"2003","journal-title":"J Nucl Med"},{"issue":"10","key":"10.1002\/hon.2078-BIB0018|hon2078-cit-0018","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1002\/hon.2078-BIB0019|hon2078-cit-0019","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1182\/blood-2007-01-068056","article-title":"Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation","volume":"110","author":"Morschhauser","year":"2007","journal-title":"Blood"},{"issue":"4","key":"10.1002\/hon.2078-BIB0020|hon2078-cit-0020","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/annonc\/mdn692","article-title":"Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma","volume":"20","author":"Esmaeli","year":"2009","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1002\/hon.2078-BIB0021|hon2078-cit-0021","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3109\/10428194.2010.534519","article-title":"90Y-Ibritumomab tiuxetan (zevalin) in heavily pretreated patients with mucosa associated lymphoid tissue lymphoma","volume":"52","author":"Hoffmann","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1002\/hon.2078-BIB0022|hon2078-cit-0022","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1002\/hon.2078-BIB0023|hon2078-cit-0023","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1136\/gut.52.11.1656","article-title":"Proposal for a new histological grading system for post treatment evaluation of gastric MALT lymphoma","volume":"52","author":"Copie-Bergman","year":"2003","journal-title":"Gut"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhon.2078","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/hon.2078\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T19:03:25Z","timestamp":1625166205000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.2078"}},"subtitle":["Radioimmunotherapy and marginal-zone lymphoma"],"short-title":[],"issued":{"date-parts":[[2013,5,20]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,3]]}},"URL":"https:\/\/doi.org\/10.1002\/hon.2078","relation":{},"ISSN":["0278-0232"],"issn-type":[{"value":"0278-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5,20]]}}}